Alisha Alaimo

President, Head of North America · Biogen

Biotechnology

Alisha Alaimo is Biogen’s president and head of North America, with prior commercial and product leadership at Novartis and Johnson & Johnson.

Last reviewed: Nov 2, 2026

Alisha Alaimo

President, Head of North America
Biogen

Last Reviewed: November 2, 2026

Executive Summary

Alisha Alaimo is Biogen’s president and head of North America, with prior commercial and product leadership at Novartis and Johnson & Johnson.

Career Highlights

  • Joined Biogen in 2017 to lead its U.S. business.
  • Leads commercial operations in the United States and Canada.
  • Spent 17 years at Novartis in global and regional assignments.

Professional Journey

Alaimo began her career in commercial positions at Johnson & Johnson. She subsequently spent 17 years at Novartis Pharmaceuticals, taking on progressively broader responsibilities in product development, brand strategy and regional leadership.

Her Novartis assignments included work in Switzerland, the United Kingdom and the United States. She worked across cardiovascular and metabolic medicine, autoimmunity, rare disease, transplantation and neuroscience, rather than remaining within a single therapeutic franchise.

Alaimo joined Biogen in 2017 to lead its U.S. business. Her work has encompassed strategy, sales, marketing, market access, key account management, advocacy and medical functions.

She now serves as president and head of North America, with responsibility for the company’s commercial operations in the United States and Canada. She is also a board member of the Biogen Foundation.

Education

Alaimo holds a B.S. from Emory University. She has also completed courses at Harvard and Tufts in clinical pharmacology, drug development and regulation, and business finance.